Drug makers try to bring back Cox-2 inhibitors

Article Abstract:

Although Merck & Company Inc. discontinued the painkiller Vioxx two years ago amid reports of increased cardiovascular problems, pharmaceutical companies are now reintroducing this class of drugs, COX-2 inhibitors. Novartis AG will introduce Prexige in Europe, and Merck is seeking FDA approval for Arcoxia, while Pfizer Inc. is reintroducing Celebrex.

Strategy & planning, Product discontinued, United States, Planning, Complications and side effects, Novartis AG, Pfizer Inc., COX-2 inhibitors, PFE, Company business planning, Vioxx (Medication), Product discontinuation, Merck & Company Inc., NVTSY

---

Roche's pick for next CEO marks a bet on diagnostics: Schwan to push technology that spots, tracks disease; first-half net grew 24%

Article Abstract:

Swiss pharmaceutical firm Roche Holding Ltd. named Severin Schwan as its next chief executive officer, emphasizing the company's interest on tools and machines that monitor and diagnose disease. Net income rose 24% to reach $4.09 bil in the first half of 2007, with sales rising by 15%.

Executive changes & profiles, Officials and employees, Roche Holding Ltd., Financial report

---

Promotional muscle: how Glaxo marketed an ailment; an ad blitz turned Requip into a big seller to treat restless-legs syndrome

Article Abstract:

GlaxoSmithKline PLC's introduction of Requip, a medication to treat restless legs syndrome, has led to sales of over $500 million this year. Requ ip's success can be attributed to an aggressive marketing campaign by the company, which included publicizing the disorder to physicians.

Marketing procedures, United Kingdom, Marketing, Drug therapy, Company marketing practices, GlaxoSmithKline PLC, Restless legs syndrome, Requip (Medication)

Similar abstracts:

• Abstracts: Akzo Nobel brings in Henkel to win a deal for ICI: move marks new effort to jointly buy a rival, then later break it up
• Abstracts: Peugeot weighs joint venture to build vehicles for China. Tata may bid for Ford's luxury brands: Indian firm's purchase of Jaguar, Land Rover would widen reach
• Abstracts: Decision-maker's preferences modeling in the stochastic goal programming
• Abstracts: Identifying intraorganisational and interorganisational alliance conflictsua longitudinal study of an alliance pilot project in the high technology industry
• Abstracts: An unusual race to become Glaxo's next CEO. Morgan Stanley to-do list: Get boss, strategy. Liz Claiborne names pharmaceutical executive as CEO

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.